deCODE genetics (Nasdaq:DCGN) today announced that it has named Dr. Peter
Goodfellow to its Board of Directors, effective immediately.
Dr. Goodfellow was until recently Senior Vice President for Discovery Research
at GlaxoSmithKline, a position he held for the past six years. Prior to this
post, he held senior positions at SmithKline Beecham, the Balfour chair in
genetics at Cambridge University and research positions at the Imperial Cancer
Research Fund. Dr. Goodfellow received his doctorate from Oxford University
and held a postdoctoral fellowship at Stanford University.
“Throughout his career Peter has worked to bring together genetics research
and drug development. This focus makes him ideally suited to work with deCODE
as we turn our gene discoveries into developmental compounds for common diseases.
I believe his experience will be of great value to helping us to advance our
product development work and I am very pleased to welcome him to deCODE,” said
Kari Stefansson, CEO of deCODE.
About deCODE
deCODE genetics (NASDAQ:DCGN) is a global leader in applying human genetics
to develop drugs for common diseases. Our population approach has enabled
us to discover and target key biological pathways involved in conditions
ranging from heart attack to cancer. We are turning these discoveries into
new medicine to better treat and prevent many of the biggest challenges to
public health. deCODE is delivering on the promise of the new genetics.SM
Visit us on the web at www.decode.com.
Any statements contained in this presentation that relate to future plans,
events or performance are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to a number of risks and uncertainties that could cause
actual results to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, among others, those relating
to technology and product development, integration of acquired businesses,
market acceptance, government regulation and regulatory approval processes,
intellectual property rights and litigation, dependence on collaborative relationships,
ability to obtain financing, competitive products, industry trends and other
risks identified in deCODE’s filings with the Securities and Exchange Commission.
deCODE undertakes no obligation to update or alter these forward-looking statements
as a result of new information, future events or otherwise.
